1. Early diagnostic protein biomarkers for breast cancer: how far have we come?

   • Annemieke W. J. Opstal-van Winden
   • Roel C. H. Vermeulen
   • Carla H. van Gils

   Review 17 December 2011 Pages: 1 - 12

2. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer

   • Hope S. Rugo
   • A. Jo Chien
   • Maura N. Dickler

   Review Open access 24 December 2011 Pages: 13 - 20

   

3. Molecular insights on basal-like breast cancer

   • Mev Dominguez Valentin
   • Sabrina Daniela da Silva
   • Yves-Jean Bignon

   Review 11 January 2012 Pages: 21 - 30

   

4. Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model

   • Yoanne Mousseau
   • Séverine Mollard
   • Franck G. Sturtz

   Preclinical study 09 December 2011 Pages: 31 - 40

   

5. Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFκB pathway

   • Miljana Tanic
   • Magdalena Zajac
   • Beatriz Martínez-Delgado

   Preclinical study 14 December 2011 Pages: 41 - 51

   

6. A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

   • Edith Blackburn
   • Stefania Zona
   • William J. Gullick

   Preclinical study 15 December 2011 Pages: 53 - 59

   

7. T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors

   • Li-Xin Wang
   • Gregory E. Plautz

   Preclinical Study 16 December 2011 Pages: 61 - 70

   

8. Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation

   • Emman Shubbar
   • Jenny Vegfors
   • Charlotta Enerbäck

   Preclinical study 22 December 2011 Pages: 71 - 80

   

9. Biologically effective dose and breast cancer conservative treatment: is duration of radiation therapy really important?

   • Pietro Sanpaolo
   • Viviana Barbieri
   • Giampiero Ausili Cèfaro

   Preclinical study 28 December 2011 Pages: 81 - 87

   

10. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer

    • Touko Inao
    • Nanae Harashima
    • Mamoru Harada

    Preclinical Study 28 December 2011 Pages: 89 - 100

    

11. SLC22A5/OCTN2 expression in breast cancer is induced by estrogen via a novel intronic estrogen-response element (ERE)

    • Chunyu Wang
    • Ivan P. Uray
    • Powel H. Brown

    Preclinical Study 03 January 2012 Pages: 101 - 115

    

12. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin

    • Khalid Abu Ajaj
    • Ralph Graeser
    • Felix Kratz

    Preclinical Study 08 January 2012 Pages: 117 - 129

    

13. Methylation of O ⁶-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients

    • Caterina Fumagalli
    • Giancarlo Pruneri
    • Massimo Barberis

    Preclinical Study 08 January 2012 Pages: 131 - 137

    

14. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells

    • Keiko Kajitani
    • Yuka Tanaka
    • Hideki Ohdan

    Preclinical Study 20 January 2012 Pages: 139 - 155

    

15. Stromal–epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer

    • Cong Xu
    • John F. Langenheim
    • Wen Y. Chen

    Preclinical study 22 January 2012 Pages: 157 - 169

    

16. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients

    • Xiangshan Zhao
    • Sameer Mirza
    • Vimla Band

    Preclinical study Open access 22 January 2012 Pages: 171 - 180

    

17. Autologous microsurgical breast reconstruction and coronary artery bypass grafting: an anatomical study and clinical implications

    • Warren M. Rozen
    • Xuan Ye
    • Iain S. Whitaker

    Preclinical Study 22 January 2012 Pages: 181 - 198

    

18. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy

    • Rainer Girgert
    • Günter Emons
    • Carsten Gründker

    Preclinical Study Open access 31 January 2012 Pages: 199 - 205

    

19. The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

    • Karina H. Gravgaard
    • Maria B. Lyng
    • Henrik J. Ditzel

    Preclinical study 01 February 2012 Pages: 207 - 217

    

20. MUTYH gene variants and breast cancer in a Dutch case–control study

    • Astrid A. Out
    • Marijke Wasielewski
    • Peter Devilee

    Preclinical Study Open access 02 February 2012 Pages: 219 - 227

21. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers

    • Yukiko Nakamura
    • Kazuteru Oshima
    • Shinzaburo Noguchi

    Preclinical Study 08 February 2012 Pages: 229 - 236

    

22. Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer

    • Sebastian F. Schoppmann
    • Anna Berghoff
    • Peter Birner

    Preclinical study 17 February 2012 Pages: 237 - 244

    

23. Aromatase inhibitors and calcium absorption in early stage breast cancer

    • Amye Tevaarwerk
    • Mark E. Burkard
    • Karen E. Hansen

    Preclinical Study 18 February 2012 Pages: 245 - 251

    

24. An abnormal screening mammogram causes more anxiety than a palpable lump in benign breast disease

    • C. M. G. Keyzer-Dekker
    • L. van Esch
    • A. F. W. van der Steeg

    Clinical trial Open access 21 March 2012 Pages: 253 - 258

    

25. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?

    • Carole Massabeau
    • Brigitte Sigal-Zafrani
    • Alain Fourquet

    Clinical Trial 22 March 2012 Pages: 259 - 266

    

26. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study

    • J. G. H. van Nes
    • D. B. Y. Fontein
    • C. J. H. van de Velde

    Clinical trial Open access 28 March 2012 Pages: 267 - 276

    

27. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer

    • Elisabetta Munzone
    • E. Botteri
    • G. Viale

    Clinical trial 01 April 2012 Pages: 277 - 282

    

28. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

    • Marta Pestrin
    • Silvia Bessi
    • Angelo Di Leo

    Clinical trial 04 April 2012 Pages: 283 - 289

    

29. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study

    • Adedayo A. Onitilo
    • Jessica M. Engel
    • Suhail A. R. Doi

    Clinical Trial 04 April 2012 Pages: 291 - 298

    

30. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

    • Trevor J. Powles
    • Susan J. Diem
    • Steven R. Cummings

    Clinical Trial 08 April 2012 Pages: 299 - 306

    

31. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer

    • Ke-Da Yu
    • Ying Zhou
    • Zhen-Zhou Shen

    Clinical Trial 12 April 2012 Pages: 307 - 313

    

32. Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery

    • Ellen W. Levy
    • Lucinda A. Pfalzer
    • Nicole L. Stout

    Clinical Trial 19 April 2012 Pages: 315 - 324

    

33. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity

    • M. Toulmonde
    • N. Madranges
    • M. Debled

    Clinical Trial 25 April 2012 Pages: 325 - 332

    

34. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

    • Libero Santarpia
    • Yuan Qi
    • Lajos Pusztai

    Clinical Trial 27 April 2012 Pages: 333 - 343

    

35. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)

    • Tianhong Li
    • Mengye Guo
    • George W. Sledge

    Clinical trial 01 May 2012 Pages: 345 - 352

    

36. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

    • Florentia Fostira
    • Marianthi Tsitlaidou
    • George Fountzilas

    Epidemiology 21 March 2012 Pages: 353 - 362

    

37. Breast cancer incidence trends in European women aged 20–39 years at diagnosis

    • D. F. Merlo
    • M. Ceppi
    • AIRTUM WG

    Epidemiology 29 March 2012 Pages: 363 - 370

    

38. Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

    • A. H. Kamal
    • F. Camacho
    • G. Kimmick

    Epidemiology 31 March 2012 Pages: 371 - 378

    

39. Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls

    • D. B. Jeffe
    • M. Pérez
    • M. Schootman

    Epidemiology 08 April 2012 Pages: 379 - 391

    

40. Genetic polymorphisms in telomere pathway genes, telomere length, and breast cancer survival

    • Jing Shen
    • Marilie D. Gammon
    • Regina M. Santella

    Epidemiology 12 April 2012 Pages: 393 - 400

41. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel

    • Daniel L. Hertz
    • Alison A. Motsinger-Reif
    • E. Claire Dees

    Epidemiology 18 April 2012 Pages: 401 - 410

    

42. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy

    • Laura Ottini
    • Valentina Silvestri
    • Domenico Palli

    Epidemiology 18 April 2012 Pages: 411 - 418

43. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)

    • Alfred I. Neugut
    • Grace Clarke Hillyer
    • Dawn L. Hershman

    Epidemiology 22 April 2012 Pages: 419 - 428

44. Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer

    • Katie Snape
    • Elise Ruark
    • Nazneen Rahman

    Brief Report 18 April 2012 Pages: 429 - 433

45. Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat

    • Laura Cortesi
    • Arcangela De Nicolo
    • Massimo Federico

    Brief Report 22 April 2012 Pages: 435 - 441

    

46. Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer

    • Frédérique Spyratos
    • Fabien Valet
    • Patricia de Cremoux

    Letter to the Editor 12 April 2012 Pages: 443 - 448

    

47. Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents

    • Gais Kadra
    • Pascal Finetti
    • Anthony Gonçalves

    Erratum 14 February 2012 Pages: 449 - 451